Worldpay (WP) and Interpace Diagnostics Group (IDXG) Critical Contrast

Worldpay (NYSE: WP) and Interpace Diagnostics Group (NASDAQ:IDXG) are both industrials companies, but which is the better investment? We will contrast the two businesses based on the strength of their earnings, profitability, dividends, risk, valuation, analyst recommendations and institutional ownership.

Insider and Institutional Ownership

13.6% of Interpace Diagnostics Group shares are held by institutional investors. 1.3% of Worldpay shares are held by company insiders. Comparatively, 0.7% of Interpace Diagnostics Group shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Analyst Ratings

This is a summary of recent ratings and price targets for Worldpay and Interpace Diagnostics Group, as provided by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Worldpay 0 5 27 1 2.88
Interpace Diagnostics Group 0 0 3 0 3.00

Worldpay presently has a consensus target price of $83.74, suggesting a potential downside of 1.49%. Interpace Diagnostics Group has a consensus target price of $3.50, suggesting a potential upside of 224.07%. Given Interpace Diagnostics Group’s stronger consensus rating and higher possible upside, analysts clearly believe Interpace Diagnostics Group is more favorable than Worldpay.

Earnings & Valuation

This table compares Worldpay and Interpace Diagnostics Group’s gross revenue, earnings per share and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Worldpay $4.03 billion 3.75 $130.11 million $0.76 111.86
Interpace Diagnostics Group $13.09 million 2.22 -$8.33 million $3.02 0.36

Worldpay has higher revenue and earnings than Interpace Diagnostics Group. Interpace Diagnostics Group is trading at a lower price-to-earnings ratio than Worldpay, indicating that it is currently the more affordable of the two stocks.

Risk & Volatility

Worldpay has a beta of 0.62, indicating that its share price is 38% less volatile than the S&P 500. Comparatively, Interpace Diagnostics Group has a beta of 1.59, indicating that its share price is 59% more volatile than the S&P 500.


This table compares Worldpay and Interpace Diagnostics Group’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Worldpay 3.23% 52.03% 7.80%
Interpace Diagnostics Group -6.33% -5.69% -3.06%


Worldpay beats Interpace Diagnostics Group on 10 of the 15 factors compared between the two stocks.

About Worldpay

Worldpay, Inc., formerly Vantiv, Inc., is a holding company. The Company conducts its operations through its subsidiary, Vantiv Holding, LLC. The Company is a payment processor. The Company’s segments include Merchant Services and Financial Institution Services. The Company offers a range of payment processing services that enable its clients to meet their payment processing needs through a single provider. The Company enables merchants to accept and process credit, debit and prepaid payments, and provide them supporting value-added services, such as security solutions and fraud management, information solutions and interchange management. It also provides payment services to financial institutions, such as card issuer processing, payment network processing, fraud protection, card production, prepaid program management, automated teller machine (ATM) driving and network gateway and switching services.

About Interpace Diagnostics Group

Interpace Diagnostics Group, Inc., formerly PDI, Inc., is focused on developing and commercializing molecular diagnostic tests principally focused on early detection of high potential progressors to cancer and leveraging the latest technology and personalized medicine for patient diagnosis and management. The Company operates through molecular diagnostics segment. It offers molecular tests, such as PancraGen, which is a pancreatic cyst molecular test that can aid in pancreatic cyst diagnosis and pancreatic cancer risk assessment utilizing its PathFinder platform; ThyGenX, which assesses thyroid nodules for risk of malignancy, and ThyraMIR, which assesses thyroid nodules risk of malignancy utilizing a gene expression assay. Through its molecular diagnostics business, the Company provides diagnostic options for detecting genetic and other molecular alterations that are associated with gastrointestinal and endocrine cancers, which are focused on early detection of cancer.

Receive News & Ratings for Worldpay Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Worldpay and related companies with's FREE daily email newsletter.

Leave a Reply